Related references
Note: Only part of the references are listed.Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching
Chiara Oltolini et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
Anita D'Souza et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
Irwin Walker et al.
LANCET HAEMATOLOGY (2020)
Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation
Luke Mountjoy et al.
LEUKEMIA & LYMPHOMA (2020)
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolanos-Meade et al.
LANCET HAEMATOLOGY (2019)
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial
Rohtesh S. Mehta et al.
HAEMATOLOGICA (2019)
Prognostic Factors for Mortality among Day+100 Survivors after Allogeneic Hematopoietic Cell Transplantation
Sagar S. Patel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Annalisa Ruggeri et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
Uday R. Popat et al.
LANCET HAEMATOLOGY (2018)
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation
Robert J. Soiffer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
M. Mielcarek et al.
BLOOD (2016)
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
Irwin Walker et al.
LANCET ONCOLOGY (2016)
Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning
Christopher G. Kanakry et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors
Theresa Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective PREFACE
M. Tomblyn et al.
BONE MARROW TRANSPLANTATION (2009)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Juergen Finke et al.
LANCET ONCOLOGY (2009)
Prediction of nonrelapse mortality for patients surviving 100 days after allogeneic hematopoietic stem cell transplantation
J. Wojnar et al.
TRANSPLANTATION PROCEEDINGS (2007)
A scheme for defining cause of death and its application in the T cell depletion trial
Edward Copelan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation
A Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
SJ Lee et al.
BLOOD (2002)
Share Paper
